Impact of inflammation on neurotransmitter changes in major depression: An insight into the action of antidepressants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 261-267

  Leonard, Brian E ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Antidepressants; Cytokines; Depression; Inflammation

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; GLUCOCORTICOID RECEPTOR; MONOAMINE; NEUROTRANSMITTER; PROSTAGLANDIN;

ADRENAL CORTEX HYPERFUNCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; CYTOKINE RELEASE; DRUG MECHANISM; ENDOCRINE SYSTEM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; MAJOR DEPRESSION; METABOLIC SYNDROME X; MICROGLIA; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS;

ANTIDEPRESSANTS; CYTOKINES; DEPRESSION; INFLAMMATION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; INFLAMMATION; RECEPTORS, NEUROTRANSMITTER;

EID: 84889256377     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.10.018     Document Type: Article

References (99)

1. Ahmad M. Genetic disruption of COX 2 does not improve histological or behavioural outcome after traumatic brain injury in mice. J Neurosci Res 2008, 86:3605-3612.
2. Akhondzadeh S., Jafari S., Raisi F., Naseh A.A., Ghoreishi A., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double-blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
3. Anisman H., Merali Z., Haley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: co-morbidity between depressive and neurodegenerative disorder. Prog Neurobiol 2008, 85:1-74.
4. Aoki T., Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci 2012, 33:304-310.
5. Baumann P., Hiemke C., Ulrich S. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265.
6. Bertolini A. Selective COX 2 inhibitor and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002, 9:1033-1043.
7. Bezzi P., Domercq M., Brambilla L., et al. CXCR4-activated astrocyte glutamate releasevia TNF alpha:amplification of microglia triggers neurotoxicity.amplification of microglia triggers neurotoxicity. Nat Neurosci 2001, 4:702-710.
8. Blais V. COX 2 inhibitors increase the inflammatory response in brain during systemic immune stimuli. J Neurochem 2005, 95:1563-1574.
9. Bouwer C., Claasen J., Dinan T.G., Nemeroff C.B. Prednisone augmentation of treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety 2000, 12:44-50.
10. Brown E.S., Suppes T. Mood symptoms during corticosteroid therapy; A review. Harv Rev Psychiatry 1998, 5:239-246.
11. Caldwell M., O'Neill M., Earley B., Leonard B.E. Nitro-L-arginine methyl ester protects against ischaemia induced biochemical changes in hippocamal neurodegeneration in the gerbil. Hum Psychopharmacol 1996, 11:299-307.
12. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., et al. Neurobehavotal effects of interferon-alpha in cancer patients; phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-645.
13. Capuron L., Ravaud A., Neveu P.J., et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002, 7:468-473.
14. Capuron L., Ravaud A., Miller A.H., Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004, 18:205-213.
15. Choi S.-H., Aid S., Bosetti F. The distinct roles of COX 1 and COX 2 in neuroinflammation:implications for translational research. Trends Pharmacol Sci 2009, 30:174-181.
16. Colin A., Reggers J., Castronovo V., Ansseau M. Lipids, depression and suicide. Encéphale 2003, 29:49-58.
17. Connor T., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998, 62:583-606.
18. Corcoran C., Connor T.J., O'Keane V., Garland M.K. The effects of vagal nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. Neuroimmunology 2005, 12:307-309.
19. Coros M., Guilbaud O., Hjalmarsson L., Chambry J., Jeammet P. Cytokines and depression: an analogic approach. Biomed Pharmacother 2002, 56:105-110.
20. Cunnane S.C., McAdoo K.R., Horrobin D.H. n-3 Essential fatty acids decrease weight gain in genetically obese mice. Br J Nutr 2006, 56:87-91.
21. Da Silva J., Goncalves-Pereira M., Xavier M., et al. Affective disorders and risk of developing dementia:a systematic review. Br J Psychiatry 2013, 202:177-186.
22. Das U.N. Is obesity an inflammatory condition?. Nutrition 2001, 17:953-966.
23. Duman R.S. Depression: a case of neuronal life and death. Biol Psychiatry 2004, 56:140-145.
24. Duman R.S., Nakagawa S., Malberg J. Reglation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001, 25:836-844.
25. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 1996, 272:50-53.
26. Geerlings M.I., Schoevers R.A., Beckman E., et al. Depression and the risk of cognitive decline and Alzheimer's disease. Results from 2 prospective community based studies in the Netherlands. Br J Psychiatry 2000, 176:556-575.
27. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice.1. Acute treatment are acive in the forced swim test. Eur J Pharmacol 1999, 372:207-213.
28. Harkin A.J., Connor T.J., Walsh M., St John N., Kelly J.P. Seronergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
29. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., McGeer P.L. Antidepressants inhibit interferon-gamma induced microglia production of interleukin-6 and nitric oxide. Exp Neurol 2007, 206:33-42.
30. Honda T. Prostacyclin-IP signalling and prostaglandin E2-EP2/EP4 signaling both mediate joint neuroinflammation in mouse collagen induced arthritis. J Exp Med 2006, 203:325-335.
31. Horikawa H., Kato T.A., Mizoguchi Y., Monji A., Seki Y., et al. Inhibitory effects of SSRI's on interferon-gamma induced activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1306-1316.
32. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
33. Igo J., Ueno S., Yamouchi K., et al. Gene expression and association analysis of VEGF in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:658-663.
34. Isung J., Mobarrez F., Nordstrom P., et al. Low plasma VEGF associated with completed suicide. World J Biol Psychiatry 2012, 13:468-473.
35. Janelidze S., Mattei D., Westrin A., et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011, 25:335-339.
36. Jiang J., Dingledine R. Prostaglandin receptor EP2 in the cross talk of anti-inflammatory, anti-cancer and neuroprotection. TIPS 2013, 34:413-423.
37. Joca S.R., Guimaraes F.S. Inhibition of neural nitric oxide synthase in rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006, 185:298-305.
38. Johanssen D., Falk A., Marcus M.M., Svensson T.H. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2012, 10.1016/j.pnpbp.2012.06.003.
39. Kato T., Mizoguchi Y., Monji A., Horikawa H., Suzuki S.O., et al. Inhibitory effects of aripiprazole on interferon-gamma induced microglial activation via intracellular calcium regulation in vitro. J Neurochem 2008, 106:815-825.
40. Kiecolt-Glaser J.K. Stress, food and inflammation:psychoneuroimmunology and nutrition at the cutting edge. Psychosom Med 2010, 72:365-369.
41. Kielcolt-Glaser J.K., Glaser R. Methological issues in behavioural immunology research in humans. Brain Behav Immun 1988, 2:67-78.
42. Kim Y.-K., Suh I.B., Kim H., et al. The plasma levels of IL-12 in schizophrenia, major depression and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002, 7:1107-1114.
43. Kozak K.R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide into prostaglandins, thromboxane and prostacyclinglycerol esters and ethanolamide. J Biol Chem 2002, 277:44877-44885.
44. Kubera M., Liu A.H., Kenis G., Bosmans E., van Bockstaele D., Maes M. Anti-inflammatory effects of antidepressants through suppression of interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001, 21:199-206.
45. Leonard B.E. Changes in the immune system in depression and dementia. Int J Dev Neurosci 2001, 19:305-312.t.
46. Leonard B.E., Myint A-M. Inflammation and depression:is there a causal relationship woth dementia?. Neurotox Res 2006, 10:149-160.
47. Leonard B.E. How useful is psychoneuroimmunology?. In vivo 2007, 21:925-927.
48. Leonard B.E. Inflammation, depression and dementia: are they connected?. Neurochem Res 2007, 32:1749-1756.
49. Leonard B.E. The concept of depression as a dysfunction of the immune system. Mod Trends Pharmacopsychiatry 2010, 27:53-71.
50. Leonard B.E. Inflammation as the cause of the metabolic syndrome in depression. Mod Trends Pharmacopsychiatry 2013, 28:117-126.
51. Levine J., Cholestoy A., Zimmerman J. Possible antidepressant effect of minocyclne. Am J Psychiatry 1996, 153:582.
52. Lichtenstein G.R., Bola M., Man C., DeWoody K., Schaible T. Infliximab improves the quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243.
53. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors: systemic analysis of population health data. Lancet 2006, 367:1747-1757.
54. Lustman P.J., Anderson P.J., Freedland K.E. Depression and poor glycaemic control: a metanalytic review of the literature. Semin Clin Neuropsychiatry 1998, 3:102-114.
55. Lustman P.J., Anderson P.J., Freedland K.E., et al. Depression and poor glycaemic control: a metaanalytic review of the literature. Diabetes Care 2000, 23:934-942.
56. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:305-312.
57. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 1999:461,25-461,45.
58. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Psychoharmacology, the 3rd generation of progress 1995, 944-93. Raven Press, New York. F.E. Bloom (Ed.).
59. Maes M., Kenis G., Kubera M., De Baets M., Steinbusch H., Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent phosphokinase-A pathway. Mol Psychiatry 2006, 11:680-684.
60. Maes M., Leonard B.E., Myint A.-M., Kubera M. The new 5HT hypothesis of depression: cell mediated immune activation induces indoleamine 2,3-dioxygenase which leads to lower plasma tryptophan and an increase in the synthesis of detrimental tryptophan catabolites, both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:702-721.
61. Malberg J.E., Blendy J.A. Antidepressant action: to the nucleus and beyond. TIPS 2005, 26:631-638.
62. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat Med 2001, 7:541-547.
63. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K.A., et al. Enhancing neural plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003, 53:707-742.
64. Martel P., Fantino M. Mesolimbic dopaminergic system activity as a function of food reward: a microdialysis study. Pharmacol Biochem Behav 1996, 53:221-226.
65. Mattsson N. Elevated CSF levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraeoic acid in multiple sclerosis. J Intern Med 2008, 1365:2796. [DOI: 10.1111/j].
66. McGeer P.L., Kawamata T., Walker D.G., Akiyama H., Tooyama I., McGeer E.G. Microlia in neurodegenerative neurological diseases. Glia 1993, 7:84-89.
67. McIntyre R.S., Rosenbluth M., Ramasubbu R., et al. Managing medical and psychiatric comorbidity in individuals with major depression and bipolar disorder. Ann Clin Psychiatry 2012, 24:163-169.
68. Mendlewicz J., Kriwin, Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006, 21:227-231.
69. Molina-Hernandez M., Tellez-Alcantara N.P., Perez-garcia J., et al. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:380-386.
70. Mosman T.R., Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17:138-146.
71. Mueller N. COX 2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 2010, 11:31-42.
72. Mueller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., et al. The cyclo-oxygenase 2 inhibitor celecoxib has therapeutic effects on major depression: results of a double-blind, randomized, placebo controlled add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
73. Myint A.-M., Kim Y.-K., Verkerk R., Scharpe S., Steinbusch H., Leonard B.E. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98:143-151.
74. Myint A.-M., Kim Y-K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypothesis 2003, 61:519-525.
75. Myint A.-M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012, 279:1375-1385.
76. Narumiya S. Prostenoids and inflammation: a new concept arises from receptor knock-out mice. J Mol Med (Berl) 2009, 87:1015-1022.
77. Nemeroff C.B., Mayberg H.S., Krahl S.E., McNamara J., Frazer A., et al. Vagal nerve stimulation therapy in treatment resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006, 31:1345-1355.
78. Niwa K. COX 2 contributes to function hyperemia in whisker-barrel cortex. J Neurosci 2000, 20:763-770.
79. Nutt D.J. The neuropharmacology of serotonin and dopamine in depression. Int Clin Psychopharmacol 2002, 17:S1-S12. [Suppl.].
80. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkn A.J., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following systemic inflammatory challenge:implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009, 12:687-699.
81. Pace T.W.W., Miller A.H. Cytokines and glucocorticoid receptor signalling: relevance to major depression. in major depression. Ann N Y Acad Sci 2001, 1179:86-105.
82. Pariante C., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391-404.o.
83. Pepicelli O. Cox 1 and COX 2 differentially contribute to prostaglandin E 2 synthesis and lipid peroxidation after in vivo activation of NMDA receptors in rat hippocampus. J Neurochem 2005, 93:1561-1567.
84. Phillis J.W. Cyclooxygenases, lipoxygenases and epoxygenases in the CNS: their role and involvement in neurological disorders. Brain Res Rev 2006, 52:201-243.
85. Pountos I., Georgouli T., Bird H., Giannoudis P.V. Nonsteroidal anti-inflammatory drugs:prostaglandins, indications and side effects. Int J Infereron Cytokine Mediator Res 2011, 3:19-27.
86. Rush A.J., Siefert S.E. Clinical issues in considering vagal nerve stimulation for treatment resistant depression. Exp Neurol 2009, 219:36-43.
87. Serhan C.N., Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008, 153(Suppl.1):S200-S215.
88. Smith R.S. The macrophage theory of depression. Med Hypotheses 1991, 35:298-306.
89. Song C., Killeen A.A., Leonard B.E. Catalase, superoxide dismutase and glutamate peroxidase activity in neutrophils of sham-operated and olfactory bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 1994, 30:24-28.
90. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., et al. Immunological aspects in the neurobiology of suicide: elevated microglia density in schizophrenia and depression is associated with suicide. J Psychiatry Res 2008, 42:151-157.
91. Stone T.W., Stoy N., Darling L.G. An expanding range of targets for kynurenine metabolism of tryptophan. Trends Pharmacol Sci 2013, 34:136-143.
92. Tang S.W., Helmeste D.M., Leonard B.E. Antidepressant compounds: a critical review. Mod Trends Pharmacopsychiatry 2010, 27:1-19.
93. Tracey K.J. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007, 117:289-296.
94. Van Gijn J. Subarachnoid haemorrhage. Lancet 2007, 369:306-318.
95. Weber J., Lyseng-Williamson K.A., Scott L.J. Aripiprazole in major depressive disorder. CNS Drugs 2008, 22:807-813.
96. Wolf S.A., Ullrich O. Endocannabinoids and the brain immune system:new neurons at the horizon?. J Neuroendocrinol 2008, 20(Suppl. 1):15-19.
97. Wong M.L., Kling M.A., Munson P.J., Listwak S., Lieinio J., Prolo P., et al. Pronounced sustained cntral hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotrophic releasing hormone. PNAS USA 2000, 97:325-330.
98. Wong M.L., Whelan F., Deloukas P., Whittaker P., Delgado M., et al. Phosphodiesterase genes associated with susceptibility to major depression and antidepressant treatment response. PNAS, USA 2006, 103:15124-15129.
99. Xia Z., DePierre J.W., Nassberger L. Tricyclic antidepressant's inhibit interleukin 6, interleukin-1beta and tumour necrosis factor-alpha release in human blood monocytes and interleukin-2 and interferon-gamma in T cells. Immunopharmacol 1996, 34:27-37.